分享好友 环球市场首页 环球市场分类 切换频道

Influenza Vaccine Market

2024-11-1400

Report Overview

Global Influenza Vaccine Market size is expected to be worth around USD 13.9 Billion by 2033 from USD 6.7 Billion in 2023, growing at a CAGR of 7.6% during the forecast period from 2024 to 2033.

The U.S. government has launched the Vaccines National Strategic Plan for 2021–2025 to enhance the development and use of vaccines throughout all stages of life. This initiative aims to bolster vaccination infrastructure and tackle emerging health challenges, ensuring a robust defense against vaccine-preventable diseases and maintaining vaccine safety.

Recent data from the CDC showcases the effectiveness of influenza vaccines. While the effectiveness can vary, typically, flu vaccines reduce the risk of illness by about 40% to 60% when the strains in the vaccine match the circulating viruses. Despite this benefit, flu vaccination coverage in the U.S. saw a slight decline, with only 49.3% of the population vaccinated in the 2022–23 season, compared to previous years.

Influenza Vaccine Market Growth

In terms of innovation, the flu vaccine market continues to evolve with a variety of options available to meet different needs. These include high-dose vaccines targeted at older adults and various formulations such as live attenuated, recombinant, and cell-based vaccines. These advancements are crucial in enhancing the efficacy and accessibility of flu vaccines.

The public health impact of these vaccines is significant. For instance, during the 2022-2023 flu season, it is estimated that vaccinations prevented around 6 million flu cases, 65,000 hospitalizations, and 3,700 deaths in the U.S. alone. These figures highlight the crucial role that flu vaccinations play in reducing the health burden of the flu.

Furthermore, the U.S. supports several global initiatives, such as the Partnership for International Vaccine Initiatives and collaborations with organizations like Gavi, the Vaccine Alliance. These efforts are essential for the development and distribution of flu vaccines, particularly in lower-income countries, and demonstrate a long-term commitment to global vaccine accessibility and sustainability.

key Takeaways

Type Analysis

The global influenza vaccine market is segmented into live attenuated and inactivated types. In 2023, the inactivated vaccine segment held the largest market share, accounting for 92.9%. This segment is expected to grow significantly during the forecast period. The demand for efficient vaccines and the high prevalence of diseases drive this growth. Additionally, a large number of manufacturers contribute to the segment’s expansion.

Inactivated vaccines administered to children aged 6-35 months have shown an effective antibody response. This increased demand, coupled with the high incidence of influenza, supports the segment’s high CAGR. Even after the primary vaccination, inactivated vaccines reduce the risk of influenza A and B infections over a long period.

Conversely, the live attenuated vaccine segment is anticipated to grow at a slower pace. This slower growth is due to various challenges in vaccine development and adoption. Additionally, live attenuated vaccines are not recommended for certain groups, such as individuals with asthma and pregnant women.

Valency Analysis

The inactivated segment of the global influenza vaccine market is expected to experience significant growth. This is largely due to the increasing efficiency of quadrivalent vaccines, which are showing the highest Compound Annual Growth Rate (CAGR). Based on valency, the market is divided into quadrivalent and trivalent vaccines.

The quadrivalent segment dominated the market in 2023, holding a 58.2% share. It also exhibited the fastest CAGR of 7.11% during the forecast period. The high efficiency of quadrivalent vaccines against viral infections is a major driver of this growth. These vaccines are readily available in hospitals and clinics and are cost-effective.

Medical specialists’ preference for quadrivalent vaccines further supports this segment’s growth. For instance, a survey conducted in June 2022 revealed that physicians and pharmacies recommend vaccines like Fluzone High-Dose Quadrivalent for individuals above 65 years.

Additionally, the increase in product approvals has propelled the uptake of this segment. The higher approval rates lead to more options for healthcare providers, which in turn boosts market growth.

Influenza Vaccine Market Size

Age Group Analysis

In 2023, the adult segment dominated the global influenza vaccine market, holding a significant revenue share of 78.4%. This growth is attributed to increased immunization efforts and substantial vaccine doses secured by organizations like PAHO, UNICEF, and GAVI. These efforts have also contributed to higher immunization coverage among the geriatric population, highlighting the importance of adult vaccinations in reducing influenza-related hospitalizations and deaths.

The pediatric segment is expected to grow at a notable rate. This growth is driven by the high number of vaccinations administered to newborns and infants to manage influenza. The World Health Organization (WHO) and other regulatory bodies have implemented policies to ensure vaccines are provided at a primary age. They aim to vaccinate every child worldwide, enhancing immunization coverage.

The rising awareness and efforts to promote immunization among adults and children are crucial in controlling influenza outbreaks. The significant revenue share of the adult segment underscores the effectiveness of targeted immunization strategies. As these efforts continue, both segments are expected to experience substantial growth, driven by ongoing initiatives and policies aimed at increasing vaccine coverage and reducing the impact of influenza globally.

Route of Administration Analysis

The global influenza vaccine market is divided into two segments based on the route of administration: injection and nasal spray. In 2023, the injection segment dominated, accounting for 60.7% of the market revenue share. This significant growth is attributed to the wide availability of intramuscular vaccine candidates. Additionally, the robust range of injectable products and recent product adoptions have further driven the segment’s development.

The nasal spray segment is expected to be the fastest-growing segment. This is due to the increasing acceptance of nasal spray vaccines, which offer ease of self-administration and suitability for home care settings. Nasal sprays are also capable of inducing systemic immunity. Researchers are continually exploring new possibilities for nasal spray vaccines, which is likely to contribute to the segment’s growth.

Distribution Channel Analysis

The Hospital and Retail Pharmacies segment has shown significant growth in the influenza vaccine market. In 2023, this segment held a dominant 37.4% market share. The primary factors driving this growth are the large number of hospitals and pharmacies offering influenza vaccinations. Smaller institutions also play a crucial role in extensive vaccination initiatives. High influenza cases, leading to increased hospital admissions, further boost the segment’s growth.

The government suppliers segment is also expected to hold a significant market share. Government administrations run extensive vaccination programs, benefiting immunized individuals globally. Additionally, hospitals contribute to the large supply of vaccines, creating growth opportunities for this segment.

Overall, the distribution channels in the global influenza vaccine market include hospitals and retail pharmacies, government suppliers, and others. The hospitals and retail pharmacies segment leads due to the widespread availability of influenza vaccines in these facilities.

Government programs also support the segment’s growth by ensuring vaccines reach a broad population. The high incidence of influenza and subsequent hospital admissions drive the demand for vaccines, making hospitals and retail pharmacies a crucial distribution channel. This trend is expected to continue, reinforcing the importance of these segments in the influenza vaccine market.

Key Market Segments

By Type

By Valency

By Age Group

By Route of Administration

By Distribution Channel

Drivers

Enhanced Global Surveillance and Immunization Programs

The WHO and CDC are actively expanding influenza vaccination programs globally. Surveillance systems aid in customizing these programs, which have shown effectiveness in regions like Asia where extensive vaccination drives have contributed to a significant reduction in influenza and COVID-19 cases. In the 2023-2024 season, these measures helped manage the vaccine demand effectively, leveraging both national and international health resources.

Advancements and Strategic Recommendations in Vaccine Development

For the 2024-2025 flu season, updated trivalent vaccines have been recommended to protect against three major strains: H1N1, H3N2, and B/Victoria lineage. These vaccines are developed based on global surveillance data to enhance their effectiveness against the most likely virus strains to circulate each season.

Restraints

Challenges in Vaccine Development

Vaccine development is a critical but time-consuming process, typically requiring 10-15 years to ensure safety and efficacy. This extensive timeline reflects the necessary, meticulous stages of vaccine research and clinical trials. According UK Charity the typical vaccine development, from early research to final approval, can cost up to $500 million and often involves multiple phases over several years​​.

Clinical trials are particularly pivotal and protracted. Phase III trials alone, which assess vaccine safety and effectiveness among thousands of participants globally, are crucial for spotting rare side effects—some as infrequent as 1 in 10,000 which necessitates large and diverse participant pools​​.

Regulatory challenges further complicate the timeline. Diverse regulatory requirements across countries mean that manufacturers must navigate different approval processes and standards, which can introduce delays. For example, each country’s regulatory body, like the FDA in the U.S., must review and approve every stage of the vaccine manufacturing process, from the initial clinical data to the final product consistency checks​.

The strict and variable regulatory environments across regions not only extend the timeline but also significantly impact the cost and complexity of vaccine development. These factors combined underscore the critical need for international collaboration to streamline processes and accelerate the availability of vaccines, especially during global health crises.

Opportunity

Government Initiatives Boost Influenza Vaccine Market Growth

Government support for influenza vaccination is significantly enhancing market growth. The World Health Organization advises countries to include influenza vaccines in national immunization programs, providing technical and financial backing.

In the U.S., the Centers for Disease Control and Prevention recommends annual flu vaccination for individuals over six months old, noting a rise in vaccine coverage with 2.5 million additional doses administered from 2019 to 2024.

The Australian government also offers free vaccines to high-risk groups through its National Immunisation Program, underscoring the need for yearly vaccination to prevent severe complications. These initiatives are driving market expansion by increasing vaccine accessibility and public awareness.

Trends

Strengthening Influenza Immunization Efforts

The global rise in influenza cases has prompted governments to incorporate influenza vaccines into national immunization programs. Increasing public awareness about infectious diseases has further supported the systematic inclusion of these vaccines, especially through organized immunization events aimed at combating the flu.

According to the World Health Organization, comprehensive vaccination coverage is crucial in preventing the severe impacts of the influenza virus. With enhanced policies and mandatory vaccination in emerging regions, countries are aiming to reduce health burdens during flu seasons and improve community health resilience. This proactive approach in public health highlights the crucial role of vaccines in managing and mitigating influenza outbreaks globally

Regional Analysis

North American region Accounted Significant Revenue Share of the Global Influenza Vaccine Market.

North America accounted for a significant influenza vaccine market revenue share of 53%. Owing to the rapid launch of effective products along with technically advanced vaccine production facilities around the region. Additionally, the rising dominance of influenza infection in Canada and the U.S. and the increasing sales of influenza vaccines in the region are also anticipated to propel the market growth.

Europe held the second prominent position in the global market. This is attributable to the extension of vaccination coverage for high-risk individuals prominent to greater immunization extents among the European population.

Asia-Pacific is anticipated to register at the fastest CAGR during the forecast period. The growing government advantages to offer vaccines and create awareness about influenza are estimated to drive market growth through the region. Latin America and, Middle East & Africa regions anticipated to account for significant growth throughout the forecast period due to rising government efforts to get everybody vaccinated, thereby propelling the market growth.

Influenza Vaccine Market Regions

Key Regions

Key Players Analysis

Key players are driving market growth through strong product portfolios. Companies like Sanofi are expanding their manufacturing facilities and geographical reach. Sanofi, a leading biopharmaceutical company, holds a significant share of the influenza vaccine market. Other notable players include GlaxoSmithKline plc, AstraZeneca, and Abbott. These companies have a global presence and their products are marketed worldwide.

Their strategic initiatives, such as launching novel products and expanding facilities, contribute to market dominance. According to recent studies by healthcare organizations, these efforts are expected to enhance market growth. The continued investment in research and development by these key players is a crucial factor in sustaining their competitive edge and driving the overall market expansion.

Market Key Players

Recent Development

点赞 0
举报
收藏 0
评论 0
分享 0